Back to articlesMetabolic Health

AOD-9604 for Fat Loss: Why It Failed Its Trials and Why People Still Use It

AOD-9604 may be one of the most misunderstood peptides in the weight-loss market.

Updated 16 Nov 202615 min readPeptidesBooking editorial
AOD-9604 for Fat Loss: Why It Failed Its Trials and Why People Still Use It
On this page

Supporters describe it as a targeted fat-loss tool. Critics point out that it failed a large clinical obesity trial. Both statements contain some truth.

The mistake is assuming that a peptide designed around fat metabolism must automatically produce meaningful weight loss on its own.

AOD-9604 was developed from a small fragment of human growth hormone associated with lipid metabolism. The idea was to capture some of growth hormone's effects on fat without producing the broader growth-hormone effects on IGF-1 and glucose metabolism.

That idea is biologically interesting.

But when AOD-9604 was tested in more than 500 adults with obesity, it did not produce significantly greater weight loss than placebo at the trial's primary endpoint. Today, clinics and peptide communities often use AOD-9604 very differently from those early studies, sometimes alongside GLP-1 medications, calorie restriction or fasting. The important question is whether those combinations actually rescue the peptide's original promise, or whether the surrounding diet and medication are doing most of the work.

The evidence does not yet give us a definitive answer.

If you are interested to learn more about fat loss peptides and where to get it: contact us here.

What exactly is AOD-9604?

AOD-9604 is a short peptide derived from human growth hormone.

More specifically, it is based on the C-terminal portion of the growth hormone molecule.

Researchers originally became interested in this region because some preclinical studies suggested that it could influence fat metabolism without reproducing all of the effects of full-length growth hormone.

That created an attractive idea:

Could researchers separate growth hormone's effects on fat from its effects on growth and glucose metabolism?

AOD-9604 was developed around that concept.

It was investigated as a potential treatment for obesity long before today's GLP-1 medications transformed weight management.

What AOD-9604 is supposed to do

The basic theory centers on lipolysis.

Lipolysis is the process of breaking down stored triglycerides inside fat cells and releasing fatty acids that can then become available for energy.

In animal and laboratory research, AOD-9604 has been associated with increased lipolytic activity.

That is why it is often described as a "fat mobilization" peptide.

But this description needs context.

Releasing stored fat and actually losing body fat are two different processes.

A fat cell can release fatty acids into circulation.

If the body does not need that energy, those fatty acids can eventually be stored again.

AOD-9604 does not make energy balance irrelevant.

The major clinical trial failed

This is the part that should not be hidden.

AOD-9604 was tested in a relatively large Phase IIb obesity study.

The OPTIONS study enrolled 536 adults with obesity, with 502 participants randomized.

Participants received either:

  • placebo
  • 0.25 mg oral AOD-9604
  • 0.5 mg oral AOD-9604
  • 1 mg oral AOD-9604

Everyone also participated in a dietitian-supervised diet and exercise program.

The treatment period lasted 24 weeks.

The primary endpoint assessed whether any AOD-9604 group achieved significantly greater weight loss than placebo after 12 weeks.

It did not.

The company later announced that the results did not support continuing development of AOD-9604 as an obesity drug.

Does a failed trial mean the peptide does nothing?

Not necessarily.

A failed obesity trial answers a specific question:

Did the treatment produce enough additional weight loss under those trial conditions to meet the predefined clinical endpoint?

For AOD-9604, the answer was no.

That does not prove that the molecule has zero biological activity.

Earlier research suggested effects related to lipid metabolism.

The larger question is whether those biological effects translate into a meaningful clinical outcome.

So far, meaningful human weight-loss efficacy has not been established.

The modern AOD-9604 argument

Most people considering AOD-9604 today are not trying to recreate the original clinical trial.

The modern argument usually sounds more like this:

Someone is already:

  • using a GLP-1 medication
  • eating less
  • losing weight
  • exercising
  • or intentionally creating a calorie deficit

Then progress slows.

AOD-9604 is introduced with the theory that it may help make stored fat more available while the body is already demanding additional fuel.

This is a different hypothesis from:

"AOD-9604 alone causes major weight loss."

It is also why some peptide clinics still find the compound interesting despite the failed obesity program.

The supply and demand analogy

A useful way to understand the theory is to separate fat metabolism into two sides.

Supply

Stored fat must become available.

This is the lipolysis side.

Demand

The body must actually need energy.

This can happen through:

  • reduced calorie intake
  • exercise
  • normal daily energy expenditure
  • other metabolic demands

AOD-9604 is usually positioned on the supply side.

It is not primarily an appetite suppressant.

It does not create an energy deficit by itself.

Where GLP-1 medications enter the discussion

GLP-1 related medications can make maintaining a calorie deficit easier by reducing appetite and changing food intake.

That gives AOD-9604 supporters an obvious combination theory.

GLP-1 therapy handles appetite.

AOD-9604 potentially influences fat mobilization.

The mechanisms appear complementary on paper.

But there is a major evidence problem.

No published controlled human trial has established that adding AOD-9604 to a GLP-1 medication produces greater fat loss than the same GLP-1 treatment without AOD-9604.

That comparison has not been adequately tested.

What about fasting?

The same logic is often applied to fasting.

During a period without incoming food, the body gradually uses stored energy.

As glycogen availability decreases, reliance on stored fat can increase.

That makes fasting an attractive theoretical setting for a fat-mobilization compound.

But again, plausible biology is not the same as clinical proof.

The original AOD-9604 obesity program did not establish that combining the peptide with fasting improves fat loss.

And there is no strong controlled human evidence showing that AOD-9604 makes fasting more effective.

Claims that it makes fasting easier are also based mainly on anecdotal experience rather than controlled trials.

You do not need AOD-9604 to burn stored fat

This is another important point.

The human body already has systems for mobilizing stored fat.

When energy intake remains below energy expenditure, stored energy becomes available and body fat can decrease.

Exercise and metabolic medications may influence that process.

AOD-9604 is not required for fat loss to occur.

Why some people say AOD-9604 did nothing

Online experiences with AOD-9604 are extremely mixed.

Some users describe noticeable changes.

Others report spending weeks or months using it without seeing a difference.

Several explanations are possible.

The peptide may simply have limited clinical effectiveness.

But other variables can also make interpretation difficult:

  • no actual calorie deficit
  • changing GLP-1 doses
  • changing diet
  • increased or decreased exercise
  • water-weight fluctuations
  • inconsistent products
  • several peptides introduced simultaneously
  • unrealistic expectations

If several variables change at once, it becomes almost impossible to identify what AOD-9604 contributed.

A plateau is not automatically "stubborn fat"

This is especially relevant for people already using GLP-1 medications.

Weight loss rarely occurs as a perfectly straight line.

A temporary plateau can reflect:

  • lower energy requirements after losing weight
  • reduced spontaneous movement
  • changing calorie intake
  • constipation
  • menstrual-cycle changes
  • fluid retention
  • reduced training
  • loss of lean mass
  • normal short-term weight variability

Adding another peptide before understanding the plateau can create complexity without solving the problem.

A stalled scale does not automatically prove that your fat cells need another peptide.

A better three-system framework

The transcript offers a useful conceptual model if we remove the sales claims.

Think of fat-loss treatment as three different problems.

System 1: Appetite and energy intake

Can you consistently maintain an appropriate calorie intake?

This is where diet structure and medications such as GLP-1 therapies can play a role.

System 2: Fat mobilization

How is stored fat being released and made available?

This is the theoretical area where AOD-9604 is positioned.

System 3: Energy use and metabolic capacity

How effectively does the body use available fuel?

Exercise, muscle mass, mitochondrial biology and metabolic health all influence this area.

These systems overlap, but they are not interchangeable.

AOD-9604 is not MOTS-c

AOD-9604 and MOTS-c are sometimes placed together under the broad category of "fat-loss peptides."

That can be misleading.

They are discussed for different reasons.

AOD-9604 was developed around growth-hormone-related lipid metabolism.

MOTS-c is a mitochondrial-derived peptide associated with cellular energy sensing and metabolic signaling.

Asking which one is "stronger" may therefore be the wrong question.

A better question is:

What biological problem are you trying to address?

What about tesamorelin?

Tesamorelin has a stronger human clinical evidence base for one very specific fat-related indication.

An FDA-approved tesamorelin product is used to reduce excess abdominal fat in adults with HIV and lipodystrophy.

Clinical research has demonstrated reductions in visceral adipose tissue in that population.

But tesamorelin works differently.

It stimulates growth-hormone signaling and can increase IGF-1.

AOD-9604 was specifically developed to avoid producing the broader growth-hormone effects associated with the full molecule.

That makes them very different tools.

AOD-9604 and IGF-1

One of the original goals of AOD-9604 was to separate effects on fat metabolism from growth hormone's effects on IGF-1.

A 2013 publication summarized safety data from six randomized, double-blind, placebo-controlled AOD-9604 studies.

In those trials, researchers did not observe significant increases in IGF-1.

They also reported no significant adverse effect on glucose tolerance and did not detect anti-AOD-9604 antibodies in the subset tested.

That is encouraging historical safety information.

But it needs an important update.

Old safety data do not answer every modern-use question

The historical studies mainly examined oral and intravenous AOD-9604.

Modern peptide clinics frequently advertise other routes, particularly subcutaneous injection.

FDA recently reviewed AOD-9604 in the context of pharmacy compounding.

The agency found very limited human safety information for the routes currently being proposed in the compounding market.

In particular, FDA did not identify adequate human information for subcutaneous or transdermal use.

The agency also raised concerns involving:

  • potential immunogenicity
  • peptide-related impurities
  • characterization of the active ingredient
  • limited long-term safety information
  • uncertainty about serious adverse events

"It doesn't raise IGF-1" does not mean "risk free"

This is a common mistake in peptide marketing.

Avoiding one known pathway can be valuable.

But safety is broader than a single laboratory marker.

Questions still include:

  • product identity
  • dose accuracy
  • sterility
  • endotoxins
  • peptide impurities
  • immunogenicity
  • long-term exposure
  • interactions with other therapies

A peptide can avoid major IGF-1 effects and still have unresolved safety questions.

Product quality matters more with unapproved peptides

There is no FDA-approved AOD-9604 obesity medication.

That means consumers considering AOD-9604 do not have an approved reference product that guarantees a particular:

  • formulation
  • strength
  • manufacturing process
  • sterility standard
  • stability profile

This makes sourcing and clinical oversight particularly important.

A certificate showing high purity does not answer every quality question.

Who is AOD-9604 probably not for?

Based on the mechanism being proposed, several situations make little conceptual sense.

AOD-9604 is unlikely to solve the main problem if:

  • appetite is still uncontrolled
  • calorie intake remains too high for fat loss
  • the primary problem is binge eating
  • there is no consistent treatment plan
  • someone expects rapid scale changes without changing energy balance
  • several experimental compounds are being added simultaneously

It is not designed as an appetite suppressant.

It should not be marketed as one.

Who might still want to discuss it with a clinic?

The most reasonable consumer profile is much narrower than "anyone who wants to lose fat."

Someone might want to discuss AOD-9604 if:

  • weight-loss fundamentals are already established
  • appetite is reasonably controlled
  • there is a documented plateau
  • body composition is being monitored
  • the patient understands that evidence for additional benefit is weak
  • the clinic can clearly explain why it believes AOD-9604 is relevant

That does not mean the peptide has been proven to solve the plateau.

It means the question is at least being asked in the correct context.

The foundation still matters more than the peptide

Before adding AOD-9604, the basics deserve review.

Nutrition

Is calorie intake actually compatible with the weight-loss goal?

Protein

Is protein intake sufficient to support lean-mass retention?

Resistance training

Is there a reason for the body to preserve muscle during weight loss?

Activity

Has daily movement decreased as weight has fallen?

Sleep

Is poor sleep interfering with appetite, recovery and training?

Medication

Is the current metabolic treatment doing what it was intended to do?

Progress tracking

Are weight trends, waist measurements, body composition or other outcomes being monitored consistently?

Be careful with aggressive fasting claims

Fasting is often paired with AOD-9604 in online protocols.

But fasting is not automatically better because it is longer or harder.

Aggressive fasting can make it more difficult to maintain:

  • protein intake
  • muscle
  • training performance
  • hydration
  • medication tolerance

For people taking glucose-lowering therapies or with certain medical conditions, fasting may also require additional supervision.

The goal should not be:

"How long can I avoid eating?"

The goal should be a sustainable metabolic strategy.

What a good AOD-9604 consultation should explain

A clinic should be able to tell you:

  • why AOD-9604 is being considered
  • what outcome it is supposed to improve
  • what evidence supports that expectation
  • what evidence does not exist
  • whether the product is approved or experimental
  • what route is being proposed
  • how product quality is assessed
  • how progress will be measured
  • what would cause treatment to stop

If the explanation is simply:

"AOD burns stubborn fat."

that is not enough.

Questions to ask before booking an AOD-9604 clinic

The biggest mistake is expecting AOD-9604 to create the deficit

AOD-9604's entire proposed value depends on understanding what it does not do.

It does not replace appetite control.

It does not replace nutrition.

It does not replace physical activity.

It does not replace resistance training.

And it does not repeal energy balance.

Even under the most favorable interpretation of its mechanism, AOD-9604 is a narrow tool.

That may actually be the best way to think about it.

AOD-9604 is not a complete fat-loss system. It is an experimental tool aimed at one part of fat metabolism.

The bottom line

References

  1. Doctor Explains Why AOD-9604 Is the BEST Fat Loss Peptide. YT Video

  2. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee. AOD-9604 Related Bulk Drug Substances Review. December 2024.

  3. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15.

  4. Ng FM, Sun J, Sharma L, et al. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Hormone Research. 2000;53(6):274-278.

  5. Metabolic Pharmaceuticals Ltd. OPTIONS Phase IIb obesity study results. 2007.

Find care

Looking for a clinic?

Search verified clinics and practitioners, compare live availability, and book an appointment online.